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Chronic Lymphocytic Leukemia • Decision Making and Problem Solving
Objectives. The Italian Society of Hematology (SIE) and two affiliate societies (SIES and
GITMO) commissioned a project to develop clinical practice guidelines for the treat-
ment of chronic lymphocytic leukemia (CLL).
Methods. Key questions in the management of patients with CLL were formulated by
an Advisory Committee and approved by an Expert Panel of eight senior hematologists.
After a systematic review of the literature, recommendations for disease-specific and
supportive therapies were formulated and graded according to the supporting evi-
dence. Explicit consensus methods were used for providing recommendations for ques-
tions with incomplete or potentially biased evidence.
Results. It is recommended that therapy is commenced in patients with CLL when at
least one of the following are present: B-symptoms, progressive/obstructive lym-
phadenopathy or organomegaly, rapid lymphocyte doubling time, anemia or thrombocy-
topenia (of new onset, worsening or steroid-resistant). It is recommended that patients
without co-morbidity should receive fludarabine plus cyclophosphamide, whereas elder-
ly patients with co-morbidity should receive oral chlorambucil. Younger patients with
unfavorable biological risk factors should be considered for high-dose chemotherapy
and autologous or allogeneic stem cell transplantation within approved clinical trials.
Patients either relapsing rapidly after, or non-responsive to, first-line chlorambucil
should receive fludarabine-containing regimens. Patients either relapsing soon after or
not responding to fludarabine-based chemotherapy should be considered for schedules
including non-cross-reactive agents, such as alemtuzumab, possibly followed by high-
dose chemotherapy and autologous transplantation in the context of a clinical trial or
by allogeneic stem cell transplantation.
Conclusions. We describe the results of a systematic literature review and an explicit
approach to consensus techniques which resulted in recommendations for the key
therapeutic decisions in patients with CLL.
Key words: chronic lymphocytic leukemia, clinical practice guidelines, systematic
review, chemotherapy.
Haematologica 2006; 91:1662-1673
©2006 Ferrata Storti Foundation
From the Divisione di Ematologia,
Azienda Ospedaliera Papardo,
Messina, Italy (MB); Istituto di
Ematologia ed Oncologia Medica
“Seragnoli”, Università di Bologna,
Bologna, Italy (GB, PLZ, ST);
Unit of Clinical Epidemiology,
IRCCS Policlinico S. Matteo, Pavia,
Italy (GB, MM); Cattedra e U.O.
Ematologia, Università di Siena,
Siena, Italy (FL); Cattedra e U.O.
Ematologia, Università di Bari,
Bari, Italy (VL); Dipartimento di
Biotecnologie Cellulari ed
Ematologia, Università degli
Studi “La Sapienza”, Roma,
Italy (FRM, GM).
Correspondence:
Giovanni Barosi, MD, Unit of Clinical
Epidemiology, IRCCS Policlinico
S. Matteo, viale Golgi 19, 27100,
Pavia, Italy.
E-mail: barosig@smatteo.pv.it
Chronic lymphocytic leukemia (CLL)is the most common adult leukemia,accounting for 24% of all leukemias.
The median survival of patients with CLL
ranges from 5 to 10 years, but a trend to a
longer survival has become evident in the
last years, partially due to earlier diagnosis.
Infections and secondary cancers continue to
be the principal causes of death in these
patients.
New therapeutic strategies and prognostic
markers have recently been developed,
which may lead to uncertainty and variabili-
ty in the clinical management of CLL.
Therefore, the Italian Society of Hematology
(SIE) and two affiliates societies, the Italian
Society of Experimental Hematology (SIES)
and the Italian Group for Bone Marrow
Transplantation (GITMO), commissioned a
project to develop clinical practice guidelines
for the therapy of CLL. The recommenda-
tions were developed through a systematic
search of evidence and formulated according
to explicit methods for consensus develop-
ment, after balancing the health benefits and
risks. The project was intended to support
the clinical practice of hematologists, oncol-





The organization and design of this proj-
ect have been reported in a previous paper
on guidelines from SIE, SIES and GITMO.1
The first search of evidence bases was per-
formed in July 2004, but updated literature
searches were continued during the project
duration. The grading system chosen is the
one designed by the Scottish Intercollegiate
Guideline Network (SIGN). The draft rec-
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ommendations were reviewed by an external panel of
two internationally recognized experts in the field and
by the presidents of the SIE, SIES and GITMO scientif-
ic societies. The present guidelines were developed
according to the best quality criteria, and adhere to the
AGREE items with a few exceptions. These guidelines
are reported according to the Conference on Guideline
Standardization checklist. Updating of the present
guideline is expected in 2008.
Definitions
The expert panel agreed on the disease defintions to
be used in the present guidelines (Table 1).2,3 CLL stage
was defined according to Binet and Rai (Table 2).4,5
Clinical response was defined according to the revised
NCI-WG revised criteria (Table 3).6
Results
Indications to start therapy and pre-treatment
evaluations
Patients with early stage CLL (Rai 0-I, Binet A) do not
experience a survival advantage if they receive
chemotherapy with chlorambucil at diagnosis prior to
disease progression when compared to deferring treat-
ment until progression. This conclusion is based on a
meta-analysis of randomized studies (level 1+),7 and it is,
therefore, recommended that chemotherapy is only initi-
ated for patients with advanced and/or active disease.
Ongoing studies are testing the clinical benefit of early
treatment with fludarabine-based chemotherapy in a spe-
cific population of patients with stage A CLL and poor
risk biological features. As well as the traditional clinical
parameters, several novel markers have been demonstrat-
ed to have prognostic importance, independently of clini-
cal stage.8 Such markers include the presence of unmutat-
ed immunoglobulin genes (IgVH), the expression of zeta-
associated protein of 70 kD (ZAP-70), and the expression
of CD38 (level 2+ to 3).9,10 The identification of recurrent
chromosomal abnormalities, as demonstrated by fluores-
cence in situ hybridization (FISH), has been shown to be
an important marker providing relevant information on
the progression of the disease and response to therapy
(level 2+ to 3).11 The determination of the aforementioned
prognostic markers is desirable in all patients but cannot
be a mandatory requirement of clinical pratice for a vari-
ety of reasons, including the lack of harmonization and
standardization of the tests; furthermore, as yet, there is
no evidence that altering therapy on the basis of these fac-
tors confers an advantage to the patient. The decision to
treat a patient should not be taken on the basis of these
biological and molecular markers. However these factors
are useful in predicting the outcomes for individual
patients and may be useful in selected patients prior to
commencement of therapy. Therefore, it is recommended
Table 1. Definitions.
• Chronic lymphocytic leukemia: a chronic lymphoproliferative disorder in
which a diagnosis should be proven by documenting an absolute
lymphocytosis of greater than 5,000 lymphocytes/µL in the
peripheral blood. The lymphocytes should appear mature, with less than
55% of atypical cells (eg. prolymphocytes), should express CD5, CD19,
CD20, CD23, surface immunoglobulin with light chain restriction, with
coexpression of CD5/CD19 or CD20, and with a low density of surface
immunoglobulins (sIg).2
• Prolymphocytic transformation: CLL with more than 55% prolymphocytes in
the peripheral blood or bone marrow.3
Table 2. Staging systems for CLL.
System Risk level Stage Clinical features at diagnosis
Rai4 Low 0 Blood and marrow lymphocytosis
Intermediate I Lymphocytosis and lymphadenopathy
II Lymphocytosis and splenomegaly or
hepatomegaly
High III Lymphocytosis and anemia
(hemoglobin < 11 g/dL)
IV Lymphocytosis and thromboctopenia
(platelets < 100,000/µL)
Binet5 A Blood and marrow lymphocytosis and
less than three areas of palpable
lymphoid involvement
B Same with three or more areas of
palpable lymphoid involvement
C Same plus anemia or thrombocytopenia
Table 3. Categorization of clinical responses of CLL.6
Definition
Complete Response (CR) All the following criteria need to be verified for at
least 2 months:
normal physical examination and absence of
symptoms AND
no infiltrates or nodules at bone marrow biopsy AND
less than 30% bone marrow lymphocytes AND
lymphocyte count in peripheral blood lower than
4×103/µL AND
neutrophil count higher than 1.54×103/µL AND
platelet count higher than 100×103/µL AND
hemoglobin value higher than 11 g/dL.
Partial Response (PR) All the following criteria need to be verified for at
least 2 months:
over 50% decrease in size of nodes, liver and spleen
AND
neutrophil count higher than 1.5×103/µL AND
platelet count higher than 100×103/µL or improved
by at least 50% AND
hemoglobin value higher than 11 g/dL
Nodular Partial All CR criteria are fullfilled, except for persisting
Response (nPR) lymphoid nodules at bone marrow biopsy.
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that the most informative prognostic markers (FISH and
VH mutational analysis or equivalent) are studied for all
patients in clinical trials and in selected patients who are
being considered for intensive or targeted therapy.
Bone marrow biopsy and lymph node biopsies are not
required for either the diagnosis of typical B-CLL or for
prognostic assessment. However, both procedures are
recommended in the presence of atypical clinical, mor-
phologic and cytometric features, i.e. suggesting a differ-
ential diagnosis. Bone marrow and lymph node biopsies
are also recommended during the follow-up to exclude
histological transformation into aggressive non-Hodgkin’s
lymphoma (see the section “Therapy for transformed dis-
ease”).
Recommendations
The indications for initiation of disease-specific therapy in
CLL include the presence of at least one of these features: B
symptoms (i.e. fever, sweats, extreme fatigue, or weight loss),
progressive enlargement of lymph nodes or hepatosplenomegaly,
obstructive adenopathy, development or worsening of thrombocy-
topenia or anemia, immune hemolysis or thrombocytopenia not
responsive to steroids, rapid lymphocyte doubling time (grade B).
Before starting first-line treatment, the physician needs to
obtain the following information: peripheral blood count, mor-
phological examination of blood smear (typical or atypical CLL),
immunophenotypic analysis (CD5/CD19, CD20, CD5/CD23,
sIg κ/λ and CD19/CD38), serum biochemistry (serum lactate
dehydrogenase, β2-microglobulin), direct Coombs’ test, and
imaging of adenomegalies, assessed either by total body comput-
ed tomography or by the combination of chest X-ray and
abdomen ultrasound (grade D).
In patients without co-morbidity further biological parameters
associated with aggressive disease and independent of the dis-
ease stage should be assessed (Table 4). In patients who do not
need to start therapy, the monitoring strategy should include
physical examination (every 3-6 months), hematologic evalua-
tion including lymphocyte doubling time and biochemistry includ-
ing serum immunoglobulin levels (every 3-6 months), abdominal
ultrasound (every 6-12 months), chest X-ray (when informative
at diagnosis). Monitoring of basic immunophenotypic analysis is
not strictly necessary (grade D).
First-line therapy
Chlorambucil
Chlorambucil was the standard first-line therapy for
CLL until the appearance of purine analogs. It has been
suggested that long-term toxicity, such as secondary can-
cers, might be slightly increased in patients treated with
chlorambucil, as compared to patients who do not receive
therapy (level 1-). In spite of its use for many decades,
there is not a commonly accepted standard dosing sched-
ule for chlorambucil: possible chlorambucil schedules are
indicated in Table 5. Comparative, randomized and non-
randomized studies showed that higher chlorambucil
doses induce a higher response rate and a longer overall
Table 4. Biological parameters associated with aggressive dis-
ease.
• Aberrations in chromosomes 11 (11q-) or 17 (17p-)
• Lack of somatic mutations in the expressed immunoglobulin VH-genes
(IgVH unmutated profile)
• Expression of cytoplasmic ZAP-70
Table 5. Currently used therapy schedules.
Fludarabine-based regimens References
F
fludarabine 25 mg/m2/day iv (or 40 mg/sqm/day orally) for 3 days 12,16,48
fludarabine 25 mg/m2/day iv for 5 days every 4 weeks for 6 cycles
FND 49
fludarabine 30 mg/m2/day iv for 3 days
mitoxantrone 10 mg/m2/day iv day 1
dexamethasone 20 mg orally daily for 5 days
to be repeated every 28 days for a maximum of 6 cycles
FN 62
fludarabine 30 mg/m2/day iv for 3 days
mitoxantrone 10 mg/m2/day iv day 1
to be repeated every 28 days for a maximum of 6 cycles
FC 50
fludarabine 25 mg/m2/day iv for 3 days
cyclophosphamide 250-300 mg/m2/day for 3 days
to be repeated every 28 days for 5-6
FAND 51
fludarabine 25 mg/m2/day iv for 3 days
Ara-C 700 mg/m2 for 3 days
novantrone 10 mg/m2 the first day
dexamethasone 10 mg iv twice daily for 3 days
to be repeated every 28 days
FCM 52
fludarabine 25 mg/m2/day iv for 3 days
cyclophosphamide 200 mg/m2/day for 3 days
mitoxantrone 6 mg/m2/day iv day 1
to be repeated every 28 days for 5-6 for a maximum of 6 cycles
Chlorambucil therapy
Low-dose chlorambucil
40 mg/m2 on day 1 every 28 days 12
0.4 mg/Kg on day 1 every 2 weeks 53
0.4-0-8 mg/Kg every month 54
to be continued for at least 6 months
Intermediate/high dose chlorambucil
30 mg/m2 on day 1 and 15 each month 55
12 mg/m2/day on day 1 to 7 each month 56
10 mg/m2/day on day 1 to 6 each month 57
to be continued for at least 6 months
Chemoimmunotherapy
FR 19
Fludarabine 25 mg/m2 d 1-5 for 6 cycles
Rituximab in 1st cycle: 50 mg day 1, 325/m2 day 3 , 375/m2 day 5
then Rituximab 375 mg/m2 day 1 of cycles 2-6. 12 mg/m2/day
on days 1 to 7 each month
FCR 19
Fludarabine 25 mg/m2
Cyclophosphamide 250 mg/m2 days 1-3 every 5 weeks for 6 cycles
Rituximab 375 mg/m2 on day 0 of the 1st cycle,
then 500 mg/m2 on day 1 of cycles 2-6
Alemtuzumab 58,59,60,61
30 mg iv or sc three times a week, starting with two
administration of 3 and 10 mg, respectively, for 12-18 weeks
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survival, but also, as expected, higher hematologic toxici-
ty than standard doses (level 1+). There is no evidence
that the association of chlorambucil with steroid therapy
has a greater efficacy or equal safety.
Purine analogs
Two large randomized studies (level 1+)12,13 and a meta-
analysis of randomized studies,14 proved that fludarabine,
used as single agent and compared with chlorambucil at
standard doses, induced higher complete response rates
and improved patients’ quality of life, irrespectively of
age. Response rates were further improved by fludara-
bine-containing combination regimens, especially by the
fludarabine plus cyclophosphamide combination (Table
5), which was shown to have a higher efficacy also in
subgroups at higher risk, such as patients with del(17) or
p53 mutation.15 Thus far, no difference in median overall
survival has been observed.15
Retrospective cohort studies showed that fludarabine
did not increase the rate of secondary cancers, as com-
pared to the rate in untreated patients. However, fludara-
bine has some drawbacks, such as the increased risk of
opportunistic infections, the occurrence of fludarabine-
associated autoimmune hemolytic anemia (AIHA), and
decreased stem cell mobilization, although data support-
ing this remain controversial. It is recommended that flu-
darabine should not be combined with steroids as there is
no evidence for increased clinical efficacy whereas there
is the potential for increased risk of infections. The avail-
able evidence reported a 2-8% rate of AIHA in patients
receiving fludarabine chemotherapy, the AIHA frequency
being much lower in patients receiving the fludarabine-
cyclophosphamide combination. Patients who develop
Coombs’ positive autoimmune hemolysis during fludara-
bine therapy should not be re-exposed to fludarabine.
It is considered that complete response rates and quali-
ty of life are relevant outcomes upon which to base ther-
apeutic decisions and therefore first-line therapy with
combined fludarabine and cyclophosphamide is recom-
mended, with dose adjustment according to renal func-
tion. However, it is considered that the toxicity and side
effects of such therapy and the effects on quality of life
might counterbalance the potential efficacy in elderly
unfit patients or in patients with comorbidities.
Therefore, the Panel recommended first-line chlorambucil
in such patients.
Cladribine as single agent produced high complete
response rates, with event-free survival and overall sur-
vival rates similar to those obtained with chlorambucil;
the association of cladribine with cyclophosphamide did
not improve overall response rates or the median duration
of response.
Combination chemotherapy without purine analogs
A large meta-analysis of ten randomized studies proved
that first-line treatment with COP, CHOP, CMP or CAP
resulted in more rapid and/or frequent responses, but did
not prolong progression-free or overall survival, as com-
pared to treatment with chlorambucil, with or without
prednisolone.7 Furthermore, first-line CAP and CHOP
therapy were inferior to fludarabine, since they induced
lower overall and complete responses (level 1++).16
Immunotherapy and chemo-immunotherapy
Only one study has reported on the use of rituximab
monotherapy as first-line treatment for CLL: it reported a
low complete response rate (9%) and an average response
duration of 18 months (level 2+).17 A few studies pub-
lished in abstract form reported the application of first-
line rituximab plus cyclophosphamide, while the concur-
rent administration of fludarabine and rituximab has been
more thoroughly investigated. The latter strategy induced
complete responses in up to half of the patients and, in a
retrospective analysis compared to historical controls, it
increased the 2-year overall survival rate from 81% to
93% and the 2-year progression-free survival rate from
45% to 67%, as compared with fludarabine alone (level
2+, 2++, 1+).18-20 Rituximab combined with both fludara-
bine and cyclophosphamide (FCR) achieved even higher
complete response rates, i.e. 68% with a number of
molecular responses also reported (Table 4).21 The addi-
tion of rituximab to fludarabine and cyclophosphamide
was not apparently associated with increased hematolog-
ic and infectious complications in indolent lymphoprolif-
erative diseases. In the absence of any randomized con-
trolled trials it is considered that the addition of rituximab
to chemotherapy cannot yet be recommended as first-line
treatment of patients with CLL.
A few studies investigated alemtuzumab (Campath) as
first-line single agent therapy (Table 5). A randomized
trial is currently comparing frontline alemtuzumab with
chlorambucil in Rai stage I-IV patients with evidence of
progressive disease. Interferon-α (IFN-α) showed limited
activity as a single-agent both in patients with advanced
disease, and in untreated patients with early disease.
However, the studies applying this strategy were mostly
non-comparative and low-quality. A randomized phase II
study found no difference in response rate from the addi-
tion of interferon to fludarabine (level 2++).
Stem cell transplantation
Young patients with high-risk advanced disease have a
low probability of remaining in remission for a prolonged
period after first-line chemotherapy or chemo-
immunotherapy. Therefore it is reasonable to consider
therapy aimed at obtaining the highest rate of molecular
remissions and the longest response duration. Autologous
stem cell transplantation (SCT) is a feasible frontline
approach in 50-70% of patients, and is associated with 1-
5% transplant-related mortality (TRM). This procedure
can achieve a high rate of long-lasting complete respons-
es and also a relevant proportion of molecular responses.
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However, no plateau has been shown in survival curves,
and secondary myelodysplastic syndromes/acute
myeloid leukemias were reported in 6-8% of the
patients.
As far as allogeneic transplant is concerned, no cohort
studies have specifically addressed its use as first-line
therapy for young CLL patients: only 12 cases were
reported in the EBMT database from 1992 to 1999. It is
considered that the current evidence does not support
front-line autologous or allogeneic SCT in clinical prac-
tice.
Recommendations
Low-risk, i.e. without unfavorable biological risk factors,
younger patients and selected elderly patients, i.e. with a very
good performance status and free of co-morbidities, are recom-
mended to receive first-line therapy with fludarabine plus
cyclophosphamide (Table 3) in order to achieve the best possible
response (grade A).
Adjustment of fludarabine dose according to renal function is
suggested (grade C). Corticosteroid use alongside fludarabine
should be limited to selected cases, i.e. patients with autoimmune
cytopenia (grade D). Younger patients with unfavorable biologi-
cal prognostic factors should be considered for high-dose
chemotherapy and autologous or allogeneic stem cell transplanta-
tion, which might achieve a durable good quality complete remis-
sion. However, it is recommended that first-line autologous or allo-
geneic stem cell transplantation is performed only within
approved clinical trials (grade C).
Patients who are not candidates for or who have contra-rindi-
cations to fludarabine-based therapy should receive chlorambucil
in order to pursue the control of symptoms and a good quality of
life, while preserving overall survival (grade B). The association
of steroids with chlorambucil may be recommended only in the
case of autoimmune complications or the presence of systemic
symptoms (grade C).
Combination chemotherapy not containing purine analogs,
either with or without anthracyclines, such as COP, CHOP or
CAP, cannot be recommended as first-line therapy (grade A).
In the absence of clear advantages in efficacy and toxicity, sin-
gle agent alemtuzumab as first-line treatment cannot be recom-
mended, so far, outside of approved clinical trials.
Monitoring the response to first-line therapy
The techniques for assessing minimal residual disease
(MRD) are currently undergoing critical evaluation and
standardization. New technologies such as four-color flow
cytometry and real time quantitative polymerase chain
reaction (PCR) analysis can determine whether patients in
complete remission by NCI-WG criteria have detectable
MRD. Eradication of MRD with alemtuzumab therapy in
previously treated patients is associated with prolonged
survival.22 However, the Panel agreed that the current evi-
dence is not sufficient to define the value of MRD assess-
ment as an end-point for routine clinical practice.
Recommendations
Patients in clinical complete remission after fludarabine-based
therapy should have the following parameters assessed at the
end of the therapy and during follow-up (grade D): physical
examination (every 3-6 months), and peripheral blood count
(every 3-6 months).
Minimal residual disease assessment, performed by direct
quadruple staining with CD5, CD19, CD20 and CD79b
expression on bone marrow lymphocytes, is not recommended in
clinical practice since the eradication of minimal residual disease
cannot be recommended as a therapeutic end-point outside of clin-
ical trials (Grade D).
Maintenance therapy
Maintenance therapy with alemtuzumab proved to
increase time to progression and survival.23,24 Discordant
results were reported for infectious complications.23,24
Maintenance treatment with rituximab also produced a
small improvement in progression-free survival. A single
study demonstrated a beneficial effect of interferon-α
given as maintenance therapy in CLL patients who had
achieved a response to chemotherapy. However, in a ret-
rospective study and two randomized trials (level 2+, 1+),
including patients responsive to fludarabine, no significant
benefits were observed in terms of response duration.
Recommendations
Maintenance interferon-α is not recommended in patients
achieving a response to chemotherapy (grade B). On the basis of
current evidence, the use of alemtuzumab or rituximab as main-
tenance therapy cannot be recommended.
Second-line therapy
Purine analogs (fludarabine-naive patients)
Patients with late relapse have a high response rate to a
repetition of their first-line treatment, such as chlorambu-
cil. In contrast, patients who do not respond or relapse
early after first-line chlorambucil usually do not get any
benefit from retreatment: an overall response to fludara-
bine-based regimens can be obtained in nearly half of the
patients and a complete response in up to one fourth of
them. Higher response rates (up to 86%) can be achieved
with fludarabine plus cyclophosphamide. In chlorambucil-
refractory patients, cladrabine induced a 64% response
rate; however, the lack of evidence prevents the formula-
tion of specific recommendations on the use of purine
analogs other than fludarabine.
Anthracycline-containing combination chemotherapy
did not prove to be superior to fludarabine as second-line
treatment for chlorambucil-refractory patients.
Purine analogs (fludarabine-pretreated patients)
Around 40-67% of patients who relapse after first-line
single agent fludarabine may respond to retreatment with
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fludarabine or fludarabine plus cyclophosphamide.
However, fludarabine-refractory patients, i.e. those who
did not respond or had early (within 6 months) progres-
sion after the end of treatment, have a poor prognosis,
achieve limited response rates with fludarabine plus
cyclophosphamide, and have a short survival.
Higher response rates can be achieved with fludarabine,
cyclophosphamide and rituximab with response rates up
to 72% (complete response >13%). The overall survival is
also improved with the above regimen, as compared with
historical control patients treated with fludarabine plus
cyclophosphamide or single agent fludarabine.25 In a phase
II study reported only in abstract form, the combination of
fludarabine, cyclophosphamide, rituximab and alem-
tuzumab produced clinical responses in over half of
patients with a median survival of 21 months. Good clini-
cal outcomes were also reported following combination
therapy with fludarabine and alemtuzumab,26 or filgastrim
and alemtuzumab.27 Pentostatin-based chemotherapy and
combination with rituximab have also been tested in flu-
darabine-refractory patients, but only a few studies have
been conducted. Inconsistent data were reported on the
efficacy of cladrabine in this clinical setting. The Panel
agreed that the balance between risk and benefits of sec-
ond-line combination regimens in fludarabine-pretreated
patients has been insufficiently explored in clinical trials.
The Panel therefore recommends enrolling patients in clin-
ical trials or, for older patients, maintaining a conservative
attitude using chlorambucil.
Immunotherapy
Immunotherapy with rituximab as a single agent did
not result in clinical efficacy in patients with previously
treated CLL, even at high doses: the overall response rate
was lower than 46% and the complete response rate
below 4%. Alemtuzumab as a single agent was effective
in inducing clinical remissions in about one third of previ-
ously treated CLL patients, and also showed clinical effi-
cacy in the subset of fludarabine-refractory patients and in
non-responsive patients with p53 mutations.28
Stem cell transplantation
High-dose chemotherapy and autologous SCT has been
reported as second-line therapy in large retrospective
studies which appeared to show an incremental 5-year
overall survival (77% vs 44%) as compared with that in
historical patients treated with conventional chemothera-
py (level 2++). However, no plateau in survival curves is
reported after autologous SCT, and molecular remissions
after autologous SCT are short-lasting.29 An improvement
of 5-year overall survival (45% vs 27%) was observed
after allogeneic SCT, as compared with standard
chemotherapy, and the advantage was maintained also in
fludarabine-refractory patients. Moreover, patients after
allogeneic transplant have a realistic chance of cure, or at
least prolonged survival, at 10 years (level 2++).30,31 Due to
the high TRM, allogeneic SCT had a worse 3-year overall
survival than autologous SCT (78% vs 54%). However,
transplant modalities (e.g. stem cell donor, conditioning
intensity, in vivo purging with monoclonal antibodies, pro-
phylaxis of graft-versus-host disease) may greatly influ-
ence TRM and post-transplant relapse rates. Therefore,
the clear survival advantage conferred by autologous SCT
might not be applicable to specific patients.
Recommendations
Patients relapsing within 6 months from first-line therapy
should be treated as recommended for refractory patients (grade
D).
Patients with late relapses (beyond 6 months from the end of
first-line treatment) should be considered for further treatment
according to the recommendations for first-line therapy (see
above) (grade D).
Younger patients refractory to first-line fludarabine plus
cyclophosphamide should be considered for stem cell transplant
procedures, after disease debulking with schedules including non-
cross-reactive agents and monoclonal antibodies, within the frame
of controlled clinical studies (grade B). Those patients with no
donor and/or not suitable for autologous or allogeneic stem cell
transplantation should be considered for experimental drugs
within clinical trials.
Patients in whom first-line fails should receive fludarabine or
fludarabine-containing regimens (grade A).
Therapy for transformed disease
Richter transformation
Richter transformation occurs when CLL evolves into
an aggressive diffuse large B-cell lymphoma: this has been
reported to occur in about 3–10% of CLL patients and is
associated with rapid lymph node enlargement, fever, and
weight loss. Different combination chemotherapy regi-
mens have achieved short-lasting responses and a survival
of less than 12 months. Immunotherapy, radioim-
munotherapy and allogeneic SCT have been reported in
only a few patients.
Prolymphocytic transformation
Prolymphocytic transformation, which has been report-
ed to occur in 10% of CLL patients, is characterized by a
poor prognosis and massive splenomegaly. Fludarabine,
alemtuzumab and rituximab have been successfully used
in this clinical setting. Only a few cases have been report-
ed to have received successful autologous or allogeneic
SCT.
Recommendations
The treatment of Richter transformation should be the same as
that for aggressive non-Hodgkin’s lymphoma (grade D).
Allogeneic stem cell transplantation is recommended in younger
cases (grade D).
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Patients with prolymphocytic transformation may receive flu-
darabine-based regimens and monoclonal antibodies (grade D).
Supportive anti-infectious therapy
Infections are the most frequent complications of CLL,
accounting for up to 50% of all CLL-related deaths.
Higher infection rates are reported to be associated with
advanced stage, higher patients’ age, number of previous
treatments, type of treatment, use of steroids, use of
alemtuzumab in refractory CLL, poor response to thera-
py, hypogammaglobulinemia with low IgG levels, per-
sistent and severe neutropenia, low CD4 lymphocyte
counts and renal dysfunction. The spectrum of infections
in patients treated with standard-dose chemotherapy is
mainly bacterial; Gram-negative bacteria are a major
cause of pneumonia. Opportunistic infections typically
associated with T-cell dysfunction, including listeriosis
and P. carinii pneumonia (PCP), have been described in
patients receiving alemtuzumab or fludarabine.
Opportunistic infections are more frequently described in
refractory patients and in patients receiving steroids,
either concurrently or subsequently to purine analogs.
Herpesvirus infections, especially varicella-zoster virus
(VZV), are frequent in patients treated with fludarabine or
alemtuzumab. Most VZV infections are dermatomal,
however, morbidity may be significant. Finally,
cytomegalovirus (CMV) reactivation has been reported in
10-25% of patients treated with alemtuzumab.
Vaccinations
No controlled studies have evaluated the clinical effica-
cy of anti-infectious vaccinations in patients with CLL.
Modest and short-lasting serological responses to a vari-
ety of vaccines (influenza vaccine, pneumococcal polysac-
charide vaccine, Haemophilus influenzae b conjugate vac-
cine and tetanus toxoid antigen) have been reported.
Booster vaccine doses were also of little value. A more
effective antibody response has been recorded in younger
patients, with less advanced disease and normal, or
almost normal, immunoglobulin levels (i.e. IgG level >700
mg/ dL). Moreover, in CLL patients, vaccines containing
live attenuated viruses could be unsafe because of the dis-
ease- and therapy-related immunosuppression.
It is deemed that the available evidence is insufficient to
establish a clinical benefit of anti-infective immunization
in CLL patients. Therefore, the Panel did not formulate
any specific recommendation.
Intravenous immunoglobulins
One randomized trial (level 1+) and further phase II
studies showed that intravenous immunoglobulins are
associated with a reduced incidence of bacterial infections
in patients with CLL with hypogammaglobulinemia
and/or a history of recurrent infections;32 therefore, it is
considered appropriate to recommend intravenous
immunoglobulins in this clinical subgroup.
Anti-infectious prophylaxis
No clinical trial has been reported that specifically
addresses anti-bacterial prophylaxis in CLL patients. In
cancer patients with granulocytopenia after cytotoxic
therapy, anti-bacterial prophylaxis reduces mortality: in
particular, fluoroquinolones reduced infection-related
mortality and the rate of clinically documented infections,
as reported by two meta-analyses of randomized con-
trolled trials enrolling patients with lymphoma or any can-
cer (level 1++).33,34 In a cohort of neutropenic patients with
hematologic malignancies, a GIMEMA randomized trial
showed a superior efficacy of prophylactic ciprofloxacin,
as compared with norfloxacin.35 Despite the above evi-
dence derived from studies enrolling patients with several
different malignancies, prophylaxis is not generally recom-
mended for neutropenic CLL patients. However, the
Expert Panel judged that both antibacterial and anti-proto-
zoal prophylaxis were appropriate in patients who had a
very high infectious risk due to disease-related or therapy-
related factors. In patients treated with fludarabine, anti-
protozoal prophylaxis is reported to be the only significant
predictor of infections. Trimethoprim-sulfamethoxazole
was chosen as the recommended agent, since it is also
effective against Listeria, Legionella, Nocardia spp. and other
bacterial infections known to occur in patients with CLL.
Since this drug is relatively well tolerated, it is suitable for
long-term use, for instance in patients who have long-last-
ing lymphocytopenia after therapy with fludarabine or
alemtuzumab. Other protozoal diseases may be more eas-
ily prevented by informing patients treated with fludara-
bine to avoid food stuffs that can contain Listeria monocyto-
genes (unpasteurized milk, some cheeses, raw vegetables,
and undercooked poultry or meat).
Therapies for CLL may also increase the risk of viral
infections, therefore, the Expert Panel recommended anti-
herpetic prophylaxis in those subgroups of patients
known to have depressed T-cell immunity. A high rate of
CMV reactivation is specifically reported during alem-
tuzumab therapy, and antiviral prophylaxis is widely used;
however, controlled studies are still onging and the clinical
benefit of such a strategy is still unknown. Therefore, it is
recommended that close monitoring of clinical and labora-
tory signs of CMV reactivation (antigenemia, PCR-based
CMV DNA detection assays) should be performed in all
CLL patients treated with alemtuzumab. The Expert Panel
also deemed that patients with clinical and laboratory evi-
dence of CMV infection should be promptly removed
from therapy and treated with gancyclovir or foscarnet.
Granulocyte colony-stimulating factor
Some trials indicate that therapy with granulocyte
growth factors (G-CSF, GM-CSF) is effective in reducing
the duration and severity of therapy-related neutropenia
in CLL patients; however, the efficacy of these growth
factors in reducing infection rate is uncertain.
Due to the scarcity of evidence specifically concerning
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CLL patients, it was considered appropriate to apply
high-quality evidence from other cancer populations. In
particular, there are two meta-analyses of randomized
controlled trials: the first (level 1++) considered an overall
cancer population with chemotherapy-induced febrile
neutropenia and reported that colony-stimulating factors
hastened neutrophil recovery and shortened hospitaliza-
tion, marginally reducing infection-related mortality (level
1++);36 the second (level 1+) considered patients with non-
Hodgkin’s lymphoma undergoing chemotherapy and
reported that colony-stimulating factors prevented febrile
neutropenia and infections.37 Indeed, current international
guidelines recommend primary prophylaxis in patients
with a high risk of febrile neutropenia and/or specific risk
factors, including decreased immune function, pre-exist-
ing neutropenia due to disease, extensive prior
chemotherapy, more advanced cancer, and poor perform-
ance status.39,39
Recommendations
Patients treated with purine analogs should receive anti-infec-
tion prophylaxis in the presence of additional risk factors for
infection, such as: age older than 65 years, previous cytotoxic
therapy, poor response to therapy, corticosteroid therapy (either
previously, concomitant or subsequent), persistent and severe
neutropenia, low CD4 lymphocyte count, low IgG levels, renal
dysfunction. Pneumocystis carinii prophylaxis should be recom-
mended for previously treated and refractory patients and to
patients exposed to corticosteroids concomitantly with fludara-
bine or before and after fludarabine. Steroids should be avoided
unless otherwise indicated (grade D).
Prophylaxis should be continued for at least 12 months and,
thereafter, while T-cell lymphocytopenia persists (CD4 count
lower than 400 cell/µL) (grade D).
Acyclovir prophylaxis should be considered for CLL patients
at higher risk for herpetic infections, who are those with a
marked T-cell reduction (CD4 count lower than 400 cell/µL)
and/or some additional risk factors such as: older age, recurrent
herpetic infection, and low serum IgG levels (grade D). Although
the duration of prophylaxis remains uncertain, it should be con-
tinued as long as these risk factors persist (grade D).
Patients treated with alemtuzumab should receive anti-proto-
zoal prophylaxis with trimethoprim-sulfamethaxazole (or nebu-
lized pentamidine) and anti herpes simplex virus prophylaxis.
Prophylaxis should continue while T-cell lymphocytopenia per-
sists (grade D).
Patients treated with alemtuzumab should undergo close
monitoring of clinical and laboratory signs of CMV reactivation
(grade D). Patients with laboratory evidence of CMV infection
should be promptly removed from therapy and treated with
appropriate anti-CMV therapy (grade D). In the presence of
severe therapy-related neutropenia (neutrophil count below 500
cells/µL) quinolone antibiotics and granulocyte growth factors
should be considered in order to prevent iatrogenic infections
(grade A).
Intravenous immunoglobulins should be considered for




The incidence of autoimmune cytopenias is significant-
ly higher in CLL patients than in the general population,
with a prevalence in CLL patients ranging from 10% to
20%. Autoimmune hemolytic anemia (AIHA) is not
always associated with a poor outcome, except for some
sporadic fatal cases. Prednisone (1-1.5 mg/Kg) is effective
in controlling hemolysis, especially when warm autoanti-
bodies are present. Similarly, chlorambucil combinations
with steroids can induce a remission of hemolysis. High-
dose intravenous immunoglobulins may be an effective rescue
therapy when an immediate, although transient, increase of
hemoglobin level may be lifesaving. Monoclonal antibodies,
mainly rituximab, have been successfully used in over 92
reported cases of AIHA, 20 of which were CLL-related: a
complete response in anemia was achieved in 21% of the
patients receiving rituximab monotherapy (overall
response rate 69%) and in 40% of the patients receiving
combination therapy, especially with steroids. However,
the use of monoclonal antibodies in this clinical setting is
still investigational, being mainly supported by anecdotal
evidence. In unresponsive patients, cyclosporine-A and splenec-
tomy can be considered: infectious and thrombotic risks of the
above therapeutic choices should be carefully considered.
CLL-related autoimmune thrombocytopenia occurs in
1-2% of patients: prednisone is effective in most cases.
High-dose intravenous immunoglobulins, cyclosporine-
A, or other cytotoxic therapy may be suggested is steroids
fail. Splenectomy was reported to produce a durable
improvement in platelet count in CLL patients; however,
its specific efficacy for CLL-related autoimmune throm-
bocythopenia has never been investigated.
CLL-related pure red-cell aplasia is a rare complication
which possibly responds to prednisolone therapy, alem-
tuzumab, cyclosporine, and rituximab.
Non-autoimmune anemia
From 9% to 29% of CLL patients have a moderate-to-
severe non-autoimmune anemia, which has a negative
prognostic impact since it correlates with advanced dis-
ease and is associated with patients having a poor
response to chemotherapy. Non-autoimmune anemia,
however, might be also associated with chemotherapy.
Erythropoietin can be effective in improving hemoglobin
and preventing transfusions in CLL patients undergoing
chemotherapy, as supported by several randomized tri-
als.40 The largest randomized trial was reported only in
abstract form and did not select patients based on ery-
thropoietin deficiency: 150 IU/kg of erythropoietin-α
three time a week resulted in a response rate of 47% in
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the treated group, with a corresponding increase in quali-
ty of life.41 Two trials selected patients with relative ery-
thropoietin deficiency. Only one of the two trials, howev-
er, compared erythropoietin-β to transfusions alone: in
the 125 enrolled CLL patients, the risk of requiring trans-
fusion and severe anemia were significantly reduced by
43% and 51%, respectively. Quality of life also improved,
paralleling the hemoglobin increase. In this clinical set-
ting, an erythropoietin-β dose of 30,000 IU given subcuta-
neously once weekly was at least as effective as 10,000 IU
twice weekly.
Splenectomy
Splenectomy has been employed for several years in
CLL patients with advanced disease in order to improve
cytopenias: a systematic review of published case series
allowed the selection of ten studies enrolling 292 patients
and reporting the hematologic outcome after splenecto-
my. Anemia and thrombocytopenia improved in most
patients after splenectomy, although, no survival benefit
was reported in a case-controlled study of 55 splenec-
tomized patients compared with 55 matched patients
receiving fludarabine.
Recommendations
Patients with advanced stage disease (Rai III-IV) undergoing
chemotherapy should receive epoetin (erythropoietin α or β at
least 30,000 IU per week or darbopoietin at least 150 µg per
week), if a relative erythropoietin deficiency has been proven
(Grade A).
Autoimmune hemolytic anemia or autoimmune thrombocy-
topenia should be treated with prednisone before starting dis-
ease-specific chemotherapy (grade C). In patients with autoim-
mune hemolytic anemia or autoimmune thrombocytopenia not
responding to corticosteroid therapy and to disease-specific
chemotherapy, a second-choice treatment can be used (i.e.
cyclophosphamide-based regimen, rituximab, high-dose intra-
venous immunoglobulins, with or without splenectomy) (grade
D).
Splenectomy is also recommended for patients without trans-
formed disease, but with a severe cytopenia (platelet count below
50×109/L, neutrophil count below 1.0×109/L, transfusion-
dependent anemia unresponsive to erythropoietin) and/or symp-
tomatic splenomegaly refractory to chemotherapy (grade D).
Prevention and treatment of tumor lysis syndrome
Following initiation of cytotoxic therapy, some meta-
bolic derangements may occur in a portion of patients
with CLL due to the rapid destruction of malignant cells
and the abrupt release of intracellular ions, nucleic acids,
proteins and their metabolites into the extracellular space,
possibly causing hyperuricemia and hyperkalemia: this
set of derangements is defined tumor lysis syndrome. Clinical
tumor lysis syndrome occurs when laboratory evidence of
tumor lysis syndrome is accompanied by renal failure,
arrythmia, or seizures. Clinical tumor lysis syndrome is
associated with a 15-20% mortality, which is directly
related to renal failure.
Overall 43 cases of tumor lysis syndrome occurring in
CLL patients being treated with fludarabine or rituximab
have been reported in medical literature since 1990.
Indeed, tumor lysis syndrome is reported in less than 1%
of CLL patients treated with fludarabine and also receiv-
ing hydration and allopurinol. Evidence (level 2++) from
studies enrolling patients with non-Hodgkin’s lym-
phomas supports the use of hydratation plus an
hypouricemic agent, either allopurinol or rasburicase: the
latter agent prevents uric acid production and thus has a
much higher efficacy than allopurinol.
Once clinical tumor lysis syndrome has developed, ras-
buricase is very effective and cost-effective in controlling
hyperuricemia and uric-acid-related nephropathy.
Recommendations
CLL patients receiving fludarabine-containing regimens
and/or monoclonal antibodies (i.e. rituximab, alemtuzumab)
should have their renal function and uric acid monitored (grade
D). Patients in whom a rapid lysis of a large number of lympho-
cytes is anticipated should receive prophylaxis with hydration
plus allopurinol (grade D). Patients with asymptomatic hyper-
uricemia preceding or developing during cytolytic therapy should
receive rasburicase (grade D).
Rasburicase is recommended for the treatment of hyper-
uricemia in clinical tumor lysis syndrome (grade C).
Discussion
The recent discovery of novel prognostic markers and
the proposal of new biological and transplant therapies
for CLL has led to a general discussion on the optimal
management for this disease. Clinical practice guidelines
should support clinicians, especially regarding novel cost-
ly therapies and/or treatments associated with a high risk,
by providing evidence-based patient management path-
ways and recommendations for specific relevant clinical
questions.
In this work, all the pieces of evidence on the key ques-
tion on therapy of CLL were collected and evaluated for
both their quality and overall consistency. Experts in the
field judged whether the body of evidence was sufficient
to provide any recommendation for clinical use of a spe-
cific therapy. The amount, type (full paper versus abstract
form), quality (study design, type of outcomes assessed,
duration of follow-up, directness) and consistency of the
different pieces of evidence were the issues ascertained in
this phase. The conceptual ground of this process is that
the relative benefit-to-risk balance of valuable therapies
results from a partially subjective process that involves
interpretation of and consensus on the evidence by the
members of an expert panel. The theoretical value of the
experts’ consensus approach to influencing practice is the
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assumption that such acknowledged experts have an
implicit and comprehensive command of the scientific
and practical information that would yield the most
appropriate recommendations. The present guidelines
suggest the use of NCI criteria to identify patients need-
ing treatment at diagnosis. The same recommendation
was provided by the British Committee for Standards in
Haematology,42 and by the result of an International
Workshop on CLL (IWCLL).43 It should be noted that NCI
criteria were published nearly 10 years ago and that they
are currently undergoing an international revision proce-
dure whose results are expected to be reported shortly.
Our recommendation to spare patients in initial and sta-
ble phase of the disease from therapy is based on strong
evidence although the randomized trials leading to this
recommendation included only chlorambucil therapy. So
far, there are no reported experiences with purine analog
therapy in this setting of patients and only a small study
with rituximab treatment, which did not result in a clini-
cal advantage. In the near future, the conclusion of large
randomized trials from French and German cooperative
groups exploring the possible advantage of early therapy
in patients in the initial phase of the disease but with bio-
logical adverse prognostic factors will give new indica-
tions for this subset of CLL cases.
The panel recommended a preferential use of fludara-
bine plus cyclophosphamide combination as first-line
therapy for the majority of patients, although the use of
chlorambucil therapy was considered appropriate in cases
with significant co-morbidity. The present guidelines
agree with the National Cancer Institute Working Group
guidelines and other ones, reported before year 2003, in
recommending the use of purine analogs in first-line treat-
ment of younger CLL patients.42,44-47 However, no other
guidelines strongly recommended the association
chemotherapy of fludarabine with cyclophosphamide as
do these guidelines which took into account the most
recent evidence.
The use of transplant procedures in CLL is a rapidly
developing issue. High dose chemotherapy with autolo-
gous stem cell transplantation now has a low risk of short
term mortality; unfortunately, a prolonged follow-up of
autotransplanted cases has clearly demonstrated a con-
stant trend to relapse. Thus, at the moment, the panel’s
recommendations were to consider these therapeutic
approaches for young cases at high risk, and within the
frame of controlled studies.
In conclusion, the main issues of CLL therapy have
been reviewed and relevant recommendations have been
proposed; these may be helpful in guiding physicians
through the huge amount of information that has been
produced in recent years. However, continuously devel-
oping knowledge on the biology and treatment of CLL
suggests that patients with this disease should be increas-
ingly treated in specialized institutions. In addition, it is
reasonable to foresee early updating of the present guide-
lines as new evidence-based information appears.
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